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CannabinoidHyperemesis Syndrome (CHS) was first described in 2004. Due to its novelty, CHS is often unrecognized by clinicians
leading to expensive workup of these patients with cyclical symptoms. It may take up to 9 years to diagnose CHS. CHS is
characterized by cyclical nausea and vomiting, abdominal pain, and an unusual compulsion to take hot showers in the presence
of chronic use of cannabinoids. Cannabicyclohexanol is a synthetic cannabinoid, popularly known as K2 spice. It is a popular
marijuana alternative among teenagers and young adults since it is readily available as herbal incense. Unlike marijuana, many
users know that K2 is not detected in conventional urine drug screens, allowing those users to conceal their intake from typical
detectionmethods. Serumor urine gas chromatographymass spectrophotometry is diagnostic, though not widely available.Thus, it
is imperative for clinicians to recognize CHS, even with negative UDS, to provide cost-effective care. We present a 38-year-old man
with a 10-year history of cannabis, and 1-year history of K2 abuse admitted with 1-week history of episodes of nausea, vomiting of
clear fluids, and epigastric discomfort. Symptoms are relieved only by hot showers. Extensive laboratory, radiologic, and endoscopic
evaluation was unrevealing. CHS was diagnosed, based on proposed criteria by Simonetti et al.
1. Introduction
Although the well-documented antiemetic properties of
cannabis account for its use in chemotherapy-induced nausea
and vomiting, interestingly cannabis and related substances
may induce vomiting as in Cannabinoid Hyperemesis Syn-
drome (CHS). The broad differentials of abdominal pain and
vomiting and the relative novelty of cannabinoid hyperemesis
condition can lead to expensive and unnecessary investiga-
tions.Diagnosis can be a challenge especially in patients using
synthetic cannabinoids like K2 which are not detected in
conventional urine drug screens. This case illustrates CHS
with the use of the synthetic cannabinoid, K2, which is less
commonly reported [1].
2. Background
Cannabinoids are the commonest illicit drug encountered
worldwide [2]. The prevalence is estimated at 3 million cases
and has increased in the past decade [3]. Although cannabis
is more commonly associated with antiemetic properties,
a paradoxical effect that results in cyclic nausea and vomiting
has been reported. This paradoxical effect, called Cannabi-
noid Hyperemesis Syndrome, was first described by Allen
et al. in 2004. It consists of cyclical abdominal pain, nausea,
and vomiting in the setting of chronic cannabinoid abuse.
An unusual and unique feature of this disorder is a strong
compulsion to bathe or shower in hot water multiple times
per day. Recognition of this syndrome is important in order
to avoid costly and unnecessary evaluation. Recognizing this
presentation also helps the patient understand and break the
cycle of drug use.
3. Case Presentation
A 38-year-old man with a self-reported long-term history
of standard cannabinoid use and K2 (a synthetic cannabis)
presented to the emergency room with a 2-week history of
nausea, vomiting, and severe abdominal pain. He smoked
3-4 times a day, occasionally up to 10 rolls a day with his
last K2 use being the night before admission. He denied any
other illicit drug use. He reported having similar episodes
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of nausea and vomiting in the past, which lasted 2-3 days
and terminated without medical intervention. Past medical
history was significant for nonulcer dyspepsia for which he
took nonprescription antacids.
On physical examination, he was afebrile with tempera-
ture of 36.8∘C, pulse of 89/min, a respiratory rate of 16/min,
a blood pressure of 115/73mmHg, and oxygen saturation of
98% while breathing ambient air. He appeared to be uncom-
fortable and was curled up in bed holding his abdomen. He
was alert, active, and oriented to time, place, and person.
He exhibited no nystagmus and had a nonfocal neurological
exam. His abdomen was soft but exhibited tenderness in the
epigastric and periumbilical regions with decreased bowel
sounds but no rebound tenderness or guarding. He noted
relief only with hot showering and, on follow-up, would often
refuse to come out of the shower to meet the physicians.
Laboratory studies showed mild leukocytosis with a
WBC count of 14 × 109/L (normal: 4–11 × 109/L). Serum
electrolyte testing revealed a sodium of 123mmol/L (normal:
135–153mmol/L), potassium of 3.4mmol/L (normal: 3.5–5.3
mmol/L), chloride of 74mmol/L (normal: 98–109mmol/L),
and bicarbonate of 21mmol/L (normal: 24–31mol/L). Blood
urea nitrogen was 160mg/dL (normal: 5–26mg/dL) and cre-
atinine was 4.78mg/dL (normal: 0.5–1.5mg/dL). No baseline
studies were available for comparison. Amylase, lipase, and
liver function tests were normal. Plain abdominal imag-
ing did not reveal any obstruction. Esophagogastroduo-
denoscopy (EGD) showed mild gastritis with unrevealing
histology andmicrobiology. Conventional urine drug screen,
which does not test for synthetic cannabinoids, was negative.
His urinalysis was normal except for the presence of hyaline
casts. His fractional excretion of sodium (FeNa) was 0.4 and
urine sodium level was 10mmol/L (normal: 10–60mmol/L).
Renal ultrasound was normal. Based on proposed diagnostic
criteria for CHS, his self-reported synthetic cannabis use, and
cyclic vomiting with negative organic evaluation, diagnosis
of Cannabinoid Hyperemesis Syndrome with prerenal acute
kidney injury was made. He was given intravenous fluids
for his hypovolemia. Ondansetron was given for his nausea
and vomiting, which offered no relief. His leukocytosis,
nausea, and renal failure completely resolved 72 hours after
admission; at that time his serum creatinine was 1.1mg/dL.
He was doing well and stayed off the K2 at outpatient follow-
up 2 weeks later.
4. Discussion
Cannabinoid Hyperemesis Syndrome (CHS) is characterized
by cyclic vomiting, abdominal pain, and compulsive need
to take hot showers [4]. The frequent showers are believed
to be a learned behavior, providing temporary relief of the
symptoms for unclear reasons. It is an episodic, recurrent
disorder with symptom free periods in-between. CHS may
be divided into periods of prodrome, hyperemesis, and
recovery [5]. The prodrome can last for months to years
and is characterized by early morning nausea, abdominal
discomfort, and fear of vomiting. This may lead to escalating
use of cannabis for self-treatment of nausea.The hyperemetic
phase is the classic CHS. This is characterized by frequent
paroxysmal nausea and vomiting which may be enough to
lead to disruption in social and occupational functioning
[6]. The associated abdominal pain is usually diffuse, mild,
and poorly characterized. It is in the hyperemetic phase that
patients prefer frequent hot showers. Hence, it has also been
called hyperemetic, hydrophilic syndrome. It is also during
this phase that they frequently undergo extensive diagnostic
workup which is usually unrevealing. These symptoms then
resolve in the hospital as cannabinoid blood levels wane
but recur when patients resume use of cannabinoids at dis-
charge. The pathophysiology of CHS is not well understood.
However, it is known that chronic marijuana use stimulates
cannabinoid receptor type 1 (CB1) in the brain resulting in
decreased peristalsis. It has been postulated that sinceCB1 lies
closer to the thermoregulatory center in the hypothalamus,
chronic hypothalamic stimulation of CB1 might be counter-
acted by hot water showering [7]. Alternative explanations
in the literature include “cutaneous steal syndrome.” Chronic
cannabinoid use causes CB1 receptor-mediated vasodilation
of the gut. It has been theorized that the redistribution
of blood from the gut to the cutaneous circulation with
hot water bathing may be related to the temporary relief
[4]. Diagnosis is often made in the presence of the cyclic
nausea and vomiting, abdominal pain, and compulsive hot
showers in the presence of chronic cannabis use. Based on the
largest case series, diagnostic criteria ofmajor and supporting
features were proposed by Simonetto et al. [3, 8]. Based on
these criteria, CHS may be diagnosed in a patient with long-
term use of cannabinoid substances and any of the following:
(i) nausea and vomiting;
(ii) abdominal pain;
(iii) symptoms relieved by hot showers or baths;
(iv) symptoms that resolve when cannabis is stopped;
(v) use of cannabinoid substance at least every week.
Other features found to be helpful include the following:
(i) younger than 50 years old;
(ii) weight loss of at least 5 kg with symptoms;
(iii) morning symptoms;
(iv) normal bowel habits;
(v) negative laboratory, radiographic and endoscopic test
results.
CHS is frequently overlooked. As reported in one case
series, average time to diagnosis is 7±4 visits to ED providers
taking up to 9 years in cases before the diagnosis is made [5].
Testing should be geared towards excluding central nervous
system, endocrine, metabolic, and gastrointestinal causes of
nausea and vomiting after a careful history and physical
examination. Cyclical Vomiting Syndrome (CVS), which
commonly occurs in the setting of migraines and depression,
should be considered in the differential diagnosis. However,
long-term use of cannabinoid substances and compulsive hot
water showering should point to CHS.
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Management of CHS can be split into the treatment of
acute hyperemetic phase and a chronic maintenance phase
[6]. In the acute hyperemetic phase, inpatient care may be
needed for supportive treatment. All classes of antiemetics
may be used for intractable nausea and vomiting. Volume
resuscitation is given for extracellular volume depletion
which may be severe enough to cause renal insufficiency
as in our case. Opioids for abdominal pain should be used
with caution due to the possibility of potentiating emesis
as a side effect. CHS patients may show esophagitis and
gastritis; therefore, acid-suppressing medications may have
a role in treatment but are by no means curative. These
supportive treatments constitute the core of care in the acute
hyperemetic phase, along with removal of the drug [6]. Care
during the chronic maintenance phase involves prevention of
relapse and patient education of the condition to help them
understand cannabinoid substance use as the cause of their
symptoms. Other measures to prevent relapse include cogni-
tive behavioral therapy and drug rehabilitation programs [9].
In conclusion, CHS is a clinical entity that should be
included in the differential diagnosis of nausea, vomiting, and
abdominal pain in any patient with a history of cannabinoid
use, especially when it is associated with obsessive hot
bathing. Recognition of this syndrome is important in order
to avoid costly and unnecessary clinical testing and to help
the patient understand and break the cycle of drug use. A
high index of suspicion is needed to make this diagnosis
especially with synthetic cannabinoids that are not detected
on conventional urine drug screens but are detected on gas
chromatography mass spectrometry which are not routinely
available [10].
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